NCT00600496 2025-11-13
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Active not recruiting
AstraZeneca
Alpha Biopharma (Jiangsu) Co., Ltd.
AbbVie
Rigshospitalet, Denmark
National Institutes of Health Clinical Center (CC)